Observed Signal · Oct 26, 2026 · Market Signal · Source: Haatch · Impact: 2/5
Virtual Science AI launches Medical Competitor AI
Haatch portfolio company Virtual Science AI has launched Medical Competitor AI, its fourth product, bringing real-time competitive intelligence to pharma medical affairs teams.
Track Haatch Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Connected Companies & Entities
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Anthill Cloud Launches for US Life Sciences
Anthill announced US availability of Anthill Cloud, a connected cloud platform for pharmaceutical, biotech and MedTech commercial and medical teams. The platform combines generative AI content creation, modular authoring and omnichannel HCP engagement in a compliance-ready ecosystem. Anthill Cloud comprises three modules — Arcane (generative AI), Activator (modular authoring with Veeva integrations) and Amplify (self-detailing/omnichannel engagement) — and is integrated with Veeva Vault PromoMats, Vault MedComms and Veeva CRM. The company positions the product to help US life sciences teams scale personalized communications, accelerate MLR approvals and reduce production overhead. The announcement was published via PR Newswire on May 19, 2026.
Aignostics Launches HETA Clinical AI for Pathology Workflow
Aignostics, a Berlin-based AI company, announced the launch of HETA Clinical, a new family of pan-cancer AI products designed to accelerate pathology workflows and reduce failed molecular tests. The first four products—HETA Quality Control, HETA Tumor Detection, HETA Mitoses, and HETA Tumor Cellularity—automate assessments such as slide quality, tumor presence, mitotic count, and tumor cellularity on H&E whole-slide images. These tasks are traditionally performed visually, which is time-consuming and prone to inter-reader variability. Pathologists at leading academic medical centers estimate that 10-20% of molecular tests fail due to insufficient tumor tissue, leading to repeat biopsies and delays. HETA Clinical helps labs prioritize cases, reduce turnaround times, and ensure adequate tumor content before testing. All products are based on HETA, Aignostics' pan-cancer tissue analysis platform, which has demonstrated cell classification performance at or exceeding expert pathologists. Aignostics also announced early access to PathoSearch, a visual search engine for pathology cases. HETA Clinical will integrate with image management systems like Techcyte Fusion®AP.
Leeds AI Startup adsilico Raises £10M for Virtual Medical Device Testing
adsilico, a University of Leeds spinout, has raised £10 million in a Series A funding round. The investment was led by PXN Ventures, with participation from existing investors Northern Gritstone and Parkwalk. Founded in 2024, adsilico develops AI-powered simulation technology that creates virtual patient populations to assess medical device performance. Their platform, Virtual Chimera, uses generative AI to create virtual hearts and blood vessels from anonymized clinical scans, combined with physics-based simulations. This allows medical device manufacturers to evaluate device performance across diverse patient demographics, aiding in development decisions such as device sizing, risk identification, and clinical trial strategy. The new funds will support expansion into neurovascular devices and increase the workforce. adsilico has already completed projects with heart valve and neurovascular device manufacturers.
Receive all future signals for Haatch & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.